inFoods IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

• Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods IBS to their patients
  
  
• Biomerica also announced that inFoods IBS clinical trial data was presented at the DDW conference May 8^th.The data showed that the inFoods IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)
  
  
• inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS drugs in the market
  

NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.  With this new finger stick blood collection option, any trained medical professional in the doctor’s office can collect the patient’s blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.  The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.

The inFoods IBS test is the first of its kind to identify specific foods that may trigger or provoke an IBS symptom, providing personalized dietary recommendations to help manage this often-debilitating condition. The test is offered as a laboratory developed test (LDT) performed in a CAP accredited, CLIA-certified high-complexity laboratory.

It is estimated that over 40 million Americans suffer from IBS, with symptoms often triggered by consumption of specific foods (which are unique to each patient). The total direct and indirect cost of IBS has been estimated at $30 billion annually in the United States alone.

"This is a significant step forward for patients, healthcare providers, and the broader medical community," said Zackary Irani, CEO of Biomerica. "By enabling the use of finger stick whole blood samples, we're making our personalized IBS therapy more convenient and easier than ever. This process reduces patient discomfort, and facilitates wider access to the inFoods IBS test, allowing healthcare providers in a variety of settings to efficiently use inFoods IBS and initiate appropriate treatment plans."